These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 6808973)

  • 1. Complete metal ion requirement of influenza virus N1 neuraminidases. Brief report.
    Carroll SM; Paulson JC
    Arch Virol; 1982; 71(3):273-7. PubMed ID: 6808973
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enzymological characteristics of avian influenza A virus neuraminidase.
    Kiyotani K; Takei N; Senoo M; Takao S; Otsuki K; Tsubokura M; Yoshida T
    Microbiol Immunol; 1987; 31(11):1131-5. PubMed ID: 2451112
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Variation in the divalent cation requirements of influenza A virus N1 neuraminidases.
    Brett IC; Johansson BE
    J Biochem; 2006 Mar; 139(3):439-47. PubMed ID: 16567409
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enzymological heterogeneity of influenza B virus neuraminidase demonstrated by the fluorometric assay method.
    Kiyotani K; Takei N; Matsuo Y
    Zentralbl Bakteriol Mikrobiol Hyg A; 1985 Oct; 260(2):273-85. PubMed ID: 2867656
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nucleotide sequence of the influenza virus A/USSR/90/77 neuraminidase gene.
    Concannon P; Kwolek CJ; Salser WA
    J Virol; 1984 May; 50(2):654-6. PubMed ID: 6708174
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Strain differences in the neuraminidase specificity of subtype N 1].
    Zakstel'skaia LIa; Molibog EV; Khliustov SV; Isachenko VA
    Vopr Virusol; 1977; (6):279-82. PubMed ID: 74908
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and in vitro study of novel neuraminidase inhibitors against avian influenza virus.
    Kongkamnerd J; Cappelletti L; Prandi A; Seneci P; Rungrotmongkol T; Jongaroonngamsang N; Rojsitthisak P; Frecer V; Milani A; Cattoli G; Terregino C; Capua I; Beneduce L; Gallotta A; Pengo P; Fassina G; Miertus S; De-Eknamkul W
    Bioorg Med Chem; 2012 Mar; 20(6):2152-7. PubMed ID: 22342267
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resistance to Mutant Group 2 Influenza Virus Neuraminidases of an Oseltamivir-Zanamivir Hybrid Inhibitor.
    Wu Y; Gao F; Qi J; Bi Y; Fu L; Mohan S; Chen Y; Li X; Pinto BM; Vavricka CJ; Tien P; Gao GF
    J Virol; 2016 Dec; 90(23):10693-10700. PubMed ID: 27654293
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Ca++ on the stability of influenza virus neuraminidase.
    Baker NJ; Gandhi SS
    Arch Virol; 1976; 52(1-2):7-18. PubMed ID: 63277
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Enzymologically different characteristics between influenza A and B virus neuraminidases].
    Takei N; Kiyotani K; Senoo M; Matsuo Y
    Uirusu; 1986 Jun; 36(1):119-23. PubMed ID: 3776104
    [No Abstract]   [Full Text] [Related]  

  • 11. Inhibitor selectivity of a new class of oseltamivir analogs against viral neuraminidase over human neuraminidase enzymes.
    Albohy A; Mohan S; Zheng RB; Pinto BM; Cairo CW
    Bioorg Med Chem; 2011 May; 19(9):2817-22. PubMed ID: 21489803
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Supplementation of conventional trivalent influenza vaccine with purified viral N1 and N2 neuraminidases induces a balanced immune response without antigenic competition.
    Johansson BE; Pokorny BA; Tiso VA
    Vaccine; 2002 Feb; 20(11-12):1670-4. PubMed ID: 11858877
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of sialidase activity as a therapeutic approach.
    Glanz VY; Myasoedova VA; Grechko AV; Orekhov AN
    Drug Des Devel Ther; 2018; 12():3431-3437. PubMed ID: 30349196
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influenza viruses with receptor-binding N1 neuraminidases occur sporadically in several lineages and show no attenuation in cell culture or mice.
    Hooper KA; Crowe JE; Bloom JD
    J Virol; 2015 Apr; 89(7):3737-45. PubMed ID: 25609803
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Variation in the divalent cation requirements of influenza a virus N2 neuraminidases.
    Johansson BE; Brett IC
    J Biochem; 2003 Sep; 134(3):345-52. PubMed ID: 14561719
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influenza virus and pneumococcal neuraminidases enhance catalysis by similar yet distinct sialic acid-binding strategies.
    Klenow L; Elfageih R; Gao J; Wan H; Withers SG; de Gier JW; Daniels R
    J Biol Chem; 2023 Feb; 299(2):102891. PubMed ID: 36634846
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The rapid identification of human influenza neuraminidase N1 and N2 subtypes by ELISA.
    Barr IG; McCaig M; Durrant C; Shaw R
    Vaccine; 2006 Nov; 24(44-46):6675-8. PubMed ID: 16860447
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influenza A virus neuraminidase: regions of the protein potentially involved in virus-host interactions.
    Fanning TG; Reid AH; Taubenberger JK
    Virology; 2000 Oct; 276(2):417-23. PubMed ID: 11040132
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structural evidence for a second sialic acid binding site in avian influenza virus neuraminidases.
    Varghese JN; Colman PM; van Donkelaar A; Blick TJ; Sahasrabudhe A; McKimm-Breschkin JL
    Proc Natl Acad Sci U S A; 1997 Oct; 94(22):11808-12. PubMed ID: 9342319
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The N2 neuraminidase of human influenza virus has acquired a substrate specificity complementary to the hemagglutinin receptor specificity.
    Baum LG; Paulson JC
    Virology; 1991 Jan; 180(1):10-5. PubMed ID: 1984642
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.